Related Experiment Video
Updated: Aug 27, 2025
Detection of SARS-CoV-2 Neutralizing Antibodies using High-Throughput Fluorescent Imaging of Pseudovirus Infection
Published on: June 5, 2021
[SARS-CoV-2 neutralizing monoclonal antibodies and nanobodies: a review]
Yulei Chen1, Jinjin Lin1, Peiyi Zheng2
1College of Ocean Food and Biological Engineering, Jimei University, Xiamen 361021, Fujian, China.
Abstract:
Coronavirus disease (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), with strong contagiousness, high susceptibility and long incubation period. cell entry by SARS-CoV-2 requires the binding between the receptor-binding domain of the viral spike protein and the cellular angiotensin-converting enzyme 2 (ACE2). Here, we briefly reviewed the mechanisms underlying the interaction between SARS-CoV-2 and ACE2, and summarized the latest research progress on SARS-CoV-2 neutralizing monoclonal antibodies and nanobodies, so as to better understand the development process and drug research direction of COVID-19. This review may facilitate understanding the development of neutralizing antibody drugs for emerging infectious diseases, especially for COVID-19.
Insights
This review explores how SARS-CoV-2 enters cells via ACE2. It summarizes research on neutralizing antibodies and nanobodies for COVID-19 drug development.
Area of Science:
- Virology
- Immunology
- Drug Discovery
Background:
- Coronavirus disease (COVID-19) is a highly contagious infectious disease caused by SARS-CoV-2.
- SARS-CoV-2 cell entry depends on the spike protein's receptor-binding domain binding to ACE2.
- Understanding this interaction is crucial for developing effective treatments.
Purpose of the Study:
- To review the mechanisms of SARS-CoV-2 and ACE2 interaction.
- To summarize recent advancements in SARS-CoV-2 neutralizing monoclonal antibodies and nanobodies.
- To guide future drug research directions for COVID-19.
Main Methods:
- Literature review of existing research on SARS-CoV-2-ACE2 interactions.
- Analysis of studies on neutralizing monoclonal antibodies and nanobodies against SARS-CoV-2.
- Synthesis of current knowledge on therapeutic antibody development.
Main Results:
- Detailed explanation of the molecular mechanisms underlying SARS-CoV-2 binding to ACE2.
- Overview of the landscape of SARS-CoV-2 neutralizing antibody and nanobody research.
- Identification of promising therapeutic strategies based on antibody engineering.
Conclusions:
- The SARS-CoV-2-ACE2 interaction is a key target for antiviral therapies.
- Neutralizing antibodies and nanobodies show significant potential for COVID-19 treatment.
- This review aids in understanding the development of antibody-based drugs for emerging infectious diseases like COVID-19.
